We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Zoetis Inc. (ZTS - Free Report) , Lam Research Corp. (LRCX - Free Report) , Aon plc (AON - Free Report) and Dominion Energy, Inc. (D - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Johnson & Johnson, Zoetis and Lam Research
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Zoetis Inc. and Lam Research Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Johnson & Johnson shares have gained +2.5% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +7.9%. The Zacks analyst believes that headwinds like generic competition and pricing pressure have contributed to its performance lagging the industry. The continuing talc and opioid litigation and Stelara’s upcoming loss of exclusivity also remain a cause for concern.
However, Johnson & Johnson’s Pharma unit is performing better than the market with successful existing products and promising new products. The MedTech unit also looks promising with a strong pipeline.
Zoetis shares have outperformed the Zacks Medical - Drugs industry over the past six months (+15.1% vs. -4.0%), reflecting the company's innovative pet care portfolio and new well-received products. In Europe, business has been boosted by its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats.
Yet, stiff competition and an ongoing supply crisis remain as headwinds.
Shares of Lam Research have outperformed the Zacks Semiconductor Equipment – Wafer Fabrication industry over the past six months (+34.7% vs. +13.8%). The Zacks analyst believes that the company is benefiting from its across systems business and an ever-strengthening customer support business.
Its top line is being driven by rising NAND requirements in accelerating 5G migration, video, and new game consoles, and its foundry and logic segment.
However, growing supply chain constraints remain a headwind. Also, imposition of export curbs on China’s chip companies, cyclicality and adverse foreign currency fluctuations are overhangs.
Other noteworthy reports we are featuring today Aon plc and Dominion Energy, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy
For Immediate Release
Chicago, IL – July 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Zoetis Inc. (ZTS - Free Report) , Lam Research Corp. (LRCX - Free Report) , Aon plc (AON - Free Report) and Dominion Energy, Inc. (D - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Johnson & Johnson, Zoetis and Lam Research
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Zoetis Inc. and Lam Research Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Johnson & Johnson shares have gained +2.5% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +7.9%. The Zacks analyst believes that headwinds like generic competition and pricing pressure have contributed to its performance lagging the industry. The continuing talc and opioid litigation and Stelara’s upcoming loss of exclusivity also remain a cause for concern.
However, Johnson & Johnson’s Pharma unit is performing better than the market with successful existing products and promising new products. The MedTech unit also looks promising with a strong pipeline.
(You can read the full research report on Johnson & Johnson here >>>)
Zoetis shares have outperformed the Zacks Medical - Drugs industry over the past six months (+15.1% vs. -4.0%), reflecting the company's innovative pet care portfolio and new well-received products. In Europe, business has been boosted by its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats.
Yet, stiff competition and an ongoing supply crisis remain as headwinds.
(You can read the full research report on Zoetis here >>>)
Shares of Lam Research have outperformed the Zacks Semiconductor Equipment – Wafer Fabrication industry over the past six months (+34.7% vs. +13.8%). The Zacks analyst believes that the company is benefiting from its across systems business and an ever-strengthening customer support business.
Its top line is being driven by rising NAND requirements in accelerating 5G migration, video, and new game consoles, and its foundry and logic segment.
However, growing supply chain constraints remain a headwind. Also, imposition of export curbs on China’s chip companies, cyclicality and adverse foreign currency fluctuations are overhangs.
(You can read the full research report on Lam Research here >>>)
Other noteworthy reports we are featuring today Aon plc and Dominion Energy, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.